Xuehereti Sataer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xuehereti Sataer has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Chen Shuangfeng
Department of Urology Surgery, Sixth Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, China
1 shared publicationFeng Bingzhenga
Center for Translational Medicine of Integrated Traditional Chinese and Western Medicine, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, 530011 Nanning, China
1 shared publicationHe Chunhua
Department of Urology Surgery, Sixth Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, China
1 shared publication- Hongjun Gao
Division of Urology, Ruikang Hospital, Guangxi University of Traditional Chinese Medicine, Guangxi Integrated Chinese and Western Medicine Clinical Research Center for Kidney Disease, Nanning, China
1 shared publication Huang Hongri
R & D Center, Guangxi Taimei Rensheng Biotechnology Co Ltd, 530006 Nanning, China
1 shared publication- Jibing Chen
Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine
1 shared publication
Latest Publications
- 2 October 2022
- Published by Taylor & Francis in Neurological Research
- Vol. 45 (3) , 191-199
Exosomal microRNAs as diagnostic biomarkers and therapeutic applications in neurodegenerative diseases
Originating from slow irreversible and progressive loss and dysfunction of neurons and synapses in the nervous system, neurodegenerative diseases (NDDs) affect millions of people worldwide. Common NDDs include Parkinson’s disease, Alzheimer’s disease multiple sclerosis, Huntington’s disease, and amyotrophic lateral sclerosis. Currently, no sensitive biomarkers are available to monitor the progression and treatment response of NDDs or to predict their prognosis. Exosomes (EXOs) are small bilipid layer-enclosed extracellular vesicles containing numerous biomolecules, including proteins, nucleic acids, and lipids. Recent evidence indicates that EXOs are pathogenic participants in the spread of neurodegenerative diseases, contributing to disease progression and spread. EXOs are also important tools for diagnosis and treatment. Recently, studies have proposed exosomal microRNAs (miRNAs) as the targets for therapies or biomarkers of NDDs. In this review, we outline the latest research on the roles of exosomal miRNAs in NDDs and their applications as potential diagnostic and therapeutic biomarkers, targets, and drugs for NDDs.
- 2 October 2022
- Published by Taylor & Francis in Neurological Research
- Vol. 45 (3) , 191-199
Exosomal microRNAs as diagnostic biomarkers and therapeutic applications in neurodegenerative diseases
Originating from slow irreversible and progressive loss and dysfunction of neurons and synapses in the nervous system, neurodegenerative diseases (NDDs) affect millions of people worldwide. Common NDDs include Parkinson’s disease, Alzheimer’s disease multiple sclerosis, Huntington’s disease, and amyotrophic lateral sclerosis. Currently, no sensitive biomarkers are available to monitor the progression and treatment response of NDDs or to predict their prognosis. Exosomes (EXOs) are small bilipid layer-enclosed extracellular vesicles containing numerous biomolecules, including proteins, nucleic acids, and lipids. Recent evidence indicates that EXOs are pathogenic participants in the spread of neurodegenerative diseases, contributing to disease progression and spread. EXOs are also important tools for diagnosis and treatment. Recently, studies have proposed exosomal microRNAs (miRNAs) as the targets for therapies or biomarkers of NDDs. In this review, we outline the latest research on the roles of exosomal miRNAs in NDDs and their applications as potential diagnostic and therapeutic biomarkers, targets, and drugs for NDDs.